Citadel Advisors
AVTX icon

Citadel Advisors’s Avalo Therapeutics AVTX Stock Holding History

Citadel Advisors’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.08M Buy
112,600
+45,800
+69% +$724K ﹤0.01% 6454
2026
Q1 		$997K Buy
+66,800
New +$1.04M ﹤0.01% 7656

Other funds holding AVTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Citadel Advisors's AVTX Position: Q2 2026 in Review

Citadel Advisors increased its Avalo Therapeutics (AVTX) stake by 67% in Q2 2026, buying an estimated $2.06M and bringing the position to 323,833 shares worth $5.98M. The position accounts for ﹤0.01% of the portfolio, ranked #4422.

Citadel Advisors first reported a position in AVTX in Q4 2015 and has held it in 17 quarters since. The position peaked at $7.62M in Q4 2025. 125 funds tracked by Wall St. Rank hold AVTX as of Q2 2026.

  • Citadel Advisors held 323,833 shares of Avalo Therapeutics worth $5.98M as of Q2 2026.
  • Citadel Advisors bought 130,098 Avalo Therapeutics shares in Q2 2026, an estimated $2.06M.
  • Avalo Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #4422 holding.
  • Citadel Advisors first reported a position in Avalo Therapeutics in Q4 2015 and has held it in 17 quarters since.
  • Citadel Advisors's Avalo Therapeutics position peaked at $7.62M in Q4 2025.
  • 125 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.